27. The method of preparation as claimed in claim 19, wherein said drug is docetaxel or a pharmaceutically acceptable salt thereof.

28. ~~A method of~~ Use of a therapeutically effective amount of pharmaceutical formulation comprising triple conjugate wherein said triple conjugate comprises a polymer moiety, a protein moiety and an active drug moiety in the preparation of a medicament for treating or preventing a disease condition selected form the group comprising of neoplastic diseases, autoimmune diseases, GERD, Ulcer, Autoimmune conditions, Diabetes, Genetic conditions, Viral/ Bacterial/ Parasitic Infections, Worm conditions—, Physical conditions, Prion diseases, Nutritional deficiencies, Vitamin/Mineral deficiencies .Mitochondrial diseases, Accidents, Sexually Transmitted Diseases, Pregnancy Conditions, Breastfeeding Conditions, Birth defects, Male/ Female/ Infant/ childhood/ Adolescent conditions, Immune disorders, Balance disorders , Pain, Systemic disorders, Blood conditions, Blood vessel conditions, Nerve conditions, Muscle conditions, Heart conditions, Back/Neck/ Spinalcord conditions, Eye conditions, Brain conditions, Mental conditions, Nose conditions, Mouth conditions, Dental conditions, Foot/ Leg/ Knee conditions, upper limb condition, Shoulder conditions, Ear conditions, Lung conditions, Liver conditions, Kidney conditions, Gall bladder conditions, Pancreas conditions, Digestive conditions, Prostate conditions, Male genital conditions, Obstetrical conditions, Gynaecological conditions, Thyroid disorders, or Hearing disorders, ~~comprising administering a therapeutically effective amount of pharmaceutical formulation comprising triple conjugate wherein said triple conjugate comprises a polymer moiety, a protein moiety and an active drug moiety, to~~ in a subject in need thereof;
wherein said active drug moiety and said protein moiety are chemically different to each other; and wherein said active drug moiety is non-biological entity.

29. The ~~method~~ use of claim 28, wherein said pharmaceutical formulation is to be administered through a parenteral route.

30. The ~~method~~ use of claim 28, wherein said drug is a cytotoxic drug.

31. The ~~method~~ use of claim 28, wherein said drug is docetaxel or a pharmaceutically acceptable salt thereof.

32. The ~~method~~ use of claim ~~24~~31, wherein amount of said drug to be administered is from 10 mg to 40 mg.

33. Use of the pharmaceutical formulation of claim 1 for preparation of a medicament for treating or preventing a disease condition selected from a group comprising of neoplastic diseases, autoimmune diseases, GERD, Ulcer, Autoimmune conditions, Diabetes, Genetic conditions, Viral/ Bacterial/ Parasitic Infections, Worm conditions , Physical conditions, Prion diseases, Nutritional deficiencies, Vitamin/Mineral deficiencies .Mitochondrial diseases, Accidents, Sexually Transmitted Diseases, Pregnancy Conditions, Breastfeeding Conditions, Birth defects, Male/ Female/ Infant/ childhood/ Adolescent conditions, Immune disorders, Balance disorders , Pain, Systemic disorders, Blood conditions, Blood vessel conditions, Nerve conditions, Muscle conditions, Heart conditions, Back/Neck/ Spinalcord conditions, Eye conditions, Brain conditions, Mental conditions, Nose conditions, Mouth conditions, Dental conditions, Foot/ Leg/ Knee conditions, upper limb condition, Shoulder conditions, Ear conditions, Lung conditions, Liver conditions, Kidney conditions, Gall bladder conditions, Pancreas conditions, Digestive conditions, Prostate conditions, Male genital conditions, Obstetrical conditions, Gynaecological conditions, Thyroid disorders, Hearing disorders or a combination of disease thereof, ~~comprising administering~~ wherein a therapeutically effective amount of said formulation is to be administered to a subject in need thereof.